

## SenzaGen receives SEK 0.6 million follow-up order

Lund, June 30, 2020

**In February, SenzaGen tested chemicals for a large global company. The same company now orders additional testing for a value of SEK 0.6 million, with the unique GARD™air assay, to analyse whether selected chemical substances can cause allergic reactions in the respiratory tract. The tests will be carried out in SenzaGen's laboratory in Lund.**

"I am happy to see that our new sales organization continues to deliver results. To deepen relationships and partnerships with large global customers is essential for us to establish GARD and to grow as a company. The new order is important since it both confirms that the customer is satisfied with our collaboration and that the GARD assays are demanded despite a business climate characterized by COVID-19," says Axel Sjöblad, CEO of SenzaGen.

The customer is headquartered in Europe where research and development play a central role. With the GARD™air test, the customer can identify substances that can cause allergy in the airways, and use the results for decision making during both product development and production, which contributes to cost savings for the company and safer products to society.

### Contacts

---

**Axel Sjöblad**, CEO, SenzaGen AB

Email: [axel.sjoblad@senzagen.com](mailto:axel.sjoblad@senzagen.com) | Mobile: +46 705-35 93 51

**Tina Dackemark Lawesson**, VP Marketing & Communications

Email: [tina.lawesson@senzagen.com](mailto:tina.lawesson@senzagen.com) | Mobile: +46 708-20 29 44



## About us

---

### About GARD

GARD™ consists of a group of tests for analysing a chemical's capacity to trigger an allergic reaction in humans. The tests target companies looking to optimize their testing strategy and increase the accuracy of their test results while avoiding animal testing. With precision and reliability, GARD improves the quality of customers' decision-making and contributes to increased product safety while reducing the number of animal tests. SenzaGen is the only company at this time that can provide an *in vitro* test to determine whether a chemical causes respiratory allergies. The Company's product portfolio consists of tests for skin and respiratory allergies: GARD™skin, GARD™air, GARD™potency and GARD™skin Medical Device.

### About SenzaGen AB (publ)

SenzaGen's technology enables the replacement of animal testing with genetic testing in test tubes to determine the allergenicity of the chemicals we come in contact with in our everyday lives, such as those in cosmetics, pharmaceuticals, food products and dyes. The Company's patented tests are the most reliable on the market and provide more information than traditional evaluation methods. SenzaGen sells direct and through partners. SenzaGen has its headquarters in Lund, Sweden, and a subsidiary in the US. For more information, please visit: [www.senzagen.com](http://www.senzagen.com).

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA), and FNCA Sweden AB, +46(0)8-528 00 399, [info@fnca.se](mailto:info@fnca.se), is the company's Certified Adviser.

## Attachments

---

[SenzaGen receives SEK 0.6 million follow-up order](#)